Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.

@article{Janson1999TreatmentWH,
  title={Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.},
  author={Eva Tiensuu Janson and B. Anders Eriksson and Kjell E Oberg and Britt M Skogseid and U Ohrvall and Sten B. Nilsson and J E Westlin},
  journal={Acta oncologica},
  year={1999},
  volume={38 3},
  pages={373-7}
}
Carcinoid tumors and endocrine pancreatic tumors often express somatostatin receptors (sst). Tumor spread may be visualized by sst scintigraphy using [(111)In-DTPA-D-Phe1]-octreotide. In this study, tumor targeting therapy with [(111)In-DTPA-D-Phe1]-octreotide at high doses (6 GBq every third week) was used to treat patients with sst-expressing tumors. Five patients entered the protocol and three were evaluable for response, while all could be evaluated for toxicity. Two patient responded with… CONTINUE READING